What's Happening?
Circular Genomics, a biotechnology company focused on neurological and psychiatric precision medicine, has appointed Dr. Henrik Zetterberg to its Scientific Advisory Board. Dr. Zetterberg is a renowned expert in neurochemistry and fluid biomarkers for
neurodegenerative diseases, particularly Alzheimer's disease. His research has been pivotal in establishing blood-based biomarkers as non-invasive tools for diagnosing and staging Alzheimer's and other neurodegenerative disorders. Circular Genomics is developing circular RNA (circRNA) blood-based assays for Alzheimer's diagnosis and risk prediction, collaborating with institutions like Washington University in St. Louis. Dr. Zetterberg's expertise will support the company's mission to transform brain health diagnostics.
Why It's Important?
The appointment of Dr. Zetterberg is significant as it strengthens Circular Genomics' efforts to develop innovative diagnostics for Alzheimer's disease. His expertise in fluid biomarkers and neurodegeneration will guide the company in advancing its circRNA platform, potentially leading to earlier detection and better disease management. This development could have a profound impact on the healthcare industry by providing more precise diagnostic tools for neurodegenerative diseases, ultimately improving patient outcomes and care strategies.
